These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11133017)

  • 1. The preparation of neoglycoconjugates containing inter-saccharide phosphodiester linkages as potential anti-Leishmania vaccines.
    Routier FH; Nikolaev AV; Ferguson MA
    Glycoconj J; 1999 Dec; 16(12):773-80. PubMed ID: 11133017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines.
    Nikolaev AV; Sizova OV
    Biochemistry (Mosc); 2011 Jul; 76(7):761-73. PubMed ID: 21999537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies directed against Leishmania secreted acid phosphatase and lipophosphoglycan. Partial characterization of private and public epitopes.
    Ilg T; Harbecke D; Wiese M; Overath P
    Eur J Biochem; 1993 Oct; 217(2):603-15. PubMed ID: 7693464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parasite glycoconjugates. Part 16: Synthesis of a disaccharide and phosphorylated di- and tri-saccharides from Leishmania lipophosphoglycan.
    Ross AJ; Sizova OV; Nikolaev AV
    Carbohydr Res; 2006 Aug; 341(11):1954-64. PubMed ID: 16697981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of the major cell surface glycoconjugates of Leishmania parasites by the human serum mannan-binding protein.
    Green PJ; Feizi T; Stoll MS; Thiel S; Prescott A; McConville MJ
    Mol Biochem Parasitol; 1994 Aug; 66(2):319-28. PubMed ID: 7808481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine.
    Hewitt MC; Seeberger PH
    J Org Chem; 2001 Jun; 66(12):4233-43. PubMed ID: 11397159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards a synthetic glycoconjugate vaccine against Neisseria meningitidis A.
    Berkin A; Coxon B; Pozsgay V
    Chemistry; 2002 Oct; 8(19):4424-33. PubMed ID: 12355530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of Leishmania mexicana lipophosphoglycan.
    Ilg T; Etges R; Overath P; McConville MJ; Thomas-Oates J; Thomas J; Homans SW; Ferguson MA
    J Biol Chem; 1992 Apr; 267(10):6834-40. PubMed ID: 1551890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins.
    Russo DM; Turco SJ; Burns JM; Reed SG
    J Immunol; 1992 Jan; 148(1):202-7. PubMed ID: 1370169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential modulation of macrophage response elicited by glycoinositolphospholipids and lipophosphoglycan from Leishmania (Viannia) shawi.
    Passero LF; Assis RR; da Silva TN; Nogueira PM; Macedo DH; Pessoa NL; Campos MA; Laurenti MD; Soares RP
    Parasitol Int; 2015 Aug; 64(4):32-5. PubMed ID: 25619843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania lipophosphoglycan components: A potent target for synthetic neoglycoproteins as a vaccine candidate for leishmaniasis.
    Mohammed ASA; Tian W; Zhang Y; Peng P; Wang F; Li T
    Carbohydr Polym; 2020 Jun; 237():116120. PubMed ID: 32241437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic phospho-oligosaccharide fragments of lipophosphoglycan as acceptors for Leishmania major alpha-D-mannosylphosphate transferase.
    Brown GM; Millar AR; Masterson C; Brimacombe JS; Nikolaev AV; Ferguson MA
    Eur J Biochem; 1996 Dec; 242(2):410-6. PubMed ID: 8973660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate.
    Liu X; Siegrist S; Amacker M; Zurbriggen R; Pluschke G; Seeberger PH
    ACS Chem Biol; 2006 Apr; 1(3):161-4. PubMed ID: 17163663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species.
    McConville MJ; Schnur LF; Jaffe C; Schneider P
    Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):807-18. PubMed ID: 7575413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant.
    Bongat AF; Saksena R; Adamo R; Fujimoto Y; Shiokawa Z; Peterson DC; Fukase K; Vann WF; Kovác P
    Glycoconj J; 2010 Jan; 27(1):69-77. PubMed ID: 19757026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor.
    McConville MJ; Bacic A; Mitchell GF; Handman E
    Proc Natl Acad Sci U S A; 1987 Dec; 84(24):8941-5. PubMed ID: 3480520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of octa- and dodecamers of D-ribitol-1-phosphate and their protein conjugates.
    Fekete A; Hoogerhout P; Zomer G; Kubler-Kielb J; Schneerson R; Robbins JB; Pozsgay V
    Carbohydr Res; 2006 Sep; 341(12):2037-48. PubMed ID: 16458277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania transmission-blocking vaccines: a review.
    Tonui WK
    East Afr Med J; 1999 Feb; 76(2):93-6. PubMed ID: 10442130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic carbohydrate based anti-fungal vaccines.
    Krylov VB; Nifantiev NE
    Drug Discov Today Technol; 2020 Dec; 35-36():35-43. PubMed ID: 33388126
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycoconjugates in New World species of Leishmania: polymorphisms in lipophosphoglycan and glycoinositolphospholipids and interaction with hosts.
    de Assis RR; Ibraim IC; Nogueira PM; Soares RP; Turco SJ
    Biochim Biophys Acta; 2012 Sep; 1820(9):1354-65. PubMed ID: 22093608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.